SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on October 7, 2009, reporting events occurring on October 6 and October 7, 2009. The company is a Colorado-based entity focused on product development and regulatory submissions. Note: The request metadata referenced "Riot Platforms, Inc." and a 2009 date, but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics and Transaction Details
- Capital Raise: The Company entered into an Underwriting Agreement to sell 4,482,609 shares of Common Stock.
- Offering Price: $1.70 per share.
- Over-Allotment Option: The Underwriter (ThinkEquity LLC) was granted a 30-day option to purchase up to 672,391 additional shares.
- Net Proceeds: Approximately $7.2 million (after underwriting discounts, commissions, and estimated expenses).
- Use of Proceeds: Product development, FDA 510(k) submission activities, general corporate purposes, and working capital.
- Financial Statements: This filing does not contain audited revenue, profit, cash flow, margin, or debt data. It is a transactional report regarding a capital raise.
Material Changes and Events
The primary material event is the execution of a definitive underwriting agreement and the subsequent pricing of a public offering. The offering is expected to close on or about October 13, 2009, subject to customary closing conditions. This represents a significant change in the company's capital structure and liquidity position pending the closing of the transaction.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance product development and support FDA 510(k) submission activities, indicating a focus on regulatory approval for its products. The filing notes that the offering is subject to customary closing conditions. No specific forward-looking financial guidance or risk factors beyond standard closing contingencies are detailed in this specific 8-K text.
Investor Verification Checklist
- Verify the closing of the offering on or about October 13, 2009.
- Confirm the final number of shares sold, including any exercise of the 672,391 share over-allotment option.
- Review the Prospectus Supplement (filed October 7, 2009) for detailed risk factors and use of proceeds.
- Monitor subsequent filings for the actual cash inflow and impact on working capital.
- Check for updates on the status of the FDA 510(k) submission activities funded by this offering.